Highest-materiality recent filing
Merger completed April 6, 2026; each SWKH share converted into either 1.7264 RWAY shares or $20.59 cash plus $0.74 guaranteed cash payment.
SWK Holdings shareholders approve merger with Runway Growth Finance Corp.
11,240,819 shares voted FOR merger agreement; only 8,763 against; proposal approved.
SWK Holdings reduces credit facility from $10M to $7.5M, amends covenants
Aggregate credit commitments reduced from $10.0M to $7.5M via Seventh Amendment effective Feb 12, 2026.
SWK Holdings Q3 net income rises to $8.8M; effective yield reaches 16.9%
Q3 GAAP net income $8.8M ($0.72/diluted share) vs $3.5M ($0.28) YoY; revenue $10.9M, up 4.8%.
SWK Holdings to be acquired by Runway Growth Finance in stock/cash merger; key holder backing
Stockholders can elect cash or stock; expected guaranteed cash payment of ~$0.74/share from Parent External Adviser.
SWK Holdings to be acquired by Runway Growth Finance in ~$220M deal
Total purchase price approx. $220M based on SWK's 6/30/25 NAV; includes $75.5M in RWAY shares and ~$145M cash.
SWK Holdings receives $27.8M loan payoff from Elutia, expects $2.8M incremental income
Received $27.8M payoff from Elutia, exceeding net GAAP carrying value of $23.9M as of June 30, 2025.
SWK Holdings Q2 GAAP net income $3.5M; sells royalty portfolio, pays $4/share special dividend
GAAP net income $3.5M ($0.29/diluted share) vs $3.7M ($0.30) YoY; revenue $10.1M, -6.5%.
SWK Holdings Q1 2025 GAAP net income $4.5M, up from $0.5M; $4.00 special dividend paid
Q1 2025 GAAP net income $4.5M ($0.37/diluted share) vs $0.5M ($0.04) in Q1 2024.
SWK Holdings closes $34M royalty sale, declares $4.00 special dividend
Closed sale of majority of royalty portfolio to Soleus Capital affiliate for $34M cash.
SWK Holdings Q4 2024 net income $5.9M, revenue up 25%; monetizes royalty portfolio for $51.3M
Q4 GAAP net income $5.9M ($0.48/diluted) vs $2.8M ($0.23) YoY; total revenue $12.4M, up 25%.
SWK Holdings monetizes royalty portfolio for $51.3M; plans dividend
ANI Pharmaceuticals exercised buyout of Iluvien royalty for ~$17.3M.
SWK Holdings Reports Q3 2024 Net Income of $3.5 Million, Revenue Up 15.6%
Q3 2024 GAAP net income was $3.5 million, compared to $4.5 million in Q3 2023.
SWK Holdings appoints Adam Rice as CFO, promotes Courtney Baker to Controller
Adam Rice appointed CFO effective July 3, 2024; also named principal financial and accounting officer.
SWK Holdings authorizes $10M share repurchase program through May 2025
Board authorized up to $10M of common stock repurchases from May 16, 2024 to May 16, 2025.
SWK Holdings Q1 net income falls 80% to $0.9M on $6M loan impairment; revenue up 25.5%
GAAP net income of $0.9M ($0.07 diluted EPS) vs $4.6M ($0.36) in Q1 2023.
SWK Holdings Q4 net income $2.8M flat YoY; finance receivables up 16% to $288.4M
Q4 GAAP net income $2.8M, flat YoY; full year 2023 net income $15.9M vs $13.5M in 2022.
SWK grants Aptar exclusive option to acquire Enteris GMP assets for ~$6M plus fee
Exclusive option to buy Enteris's GMP manufacturing and clinical supply assets; option expires Jan 1, 2026.
On September 30, 2024, Marcus Pennington resigned from the Board of Directors (the “Board”) of SWK Holdings Corporation (the “Company”), effective October 1, 2024 (the “Effective Date”).
On July 8, 2024, SWK Holdings, Inc. (the “Company”) announced that on July 3, 2024, the Board of Directors (the “Board”) of the Company, appointed Adam Rice as Chief Financial Officer of the Company, effective as of July 3, 2024.
Max materiality 0.90 · Median 0.60 · Most common event earnings